Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.
Playford EG, Munro T, Mahler SM, Elliott S, Gerometta M, Hoger KL, Jones ML, Griffin P, Lynch KD, Carroll H, El Saadi D, Gilmour ME, Hughes B, Hughes K, Huang E, de Bakker C, Klein R, Scher MG, Smith IL, Wang LF, Lambert SB, Dimitrov DS, Gray PP, Broder CC.
Playford EG, et al. Among authors: munro t.
Lancet Infect Dis. 2020 Apr;20(4):445-454. doi: 10.1016/S1473-3099(19)30634-6. Epub 2020 Feb 3.
Lancet Infect Dis. 2020.
PMID: 32027842
Clinical Trial.